ACCESSWIRE

3295 articles with ACCESSWIRE

• Jupiter Wellness Acquires the Assets of Applied Biology Inc., a Leading Biotechnology Company Specializing in Hair and Skin Science

  6/21/2022

  Jupiter Wellness , Inc. (Nasdaq: JUPW ) today announced the acquisition of 100% of the assets of Applied Biology, Inc.

• Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1

  6/21/2022

  Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is exhibiting at the American College of Veterinary Internal Medicine (ACVIM) Forum, which takes place June 23 - 25, 2022 in Austin, TX.

• Avinger Expands International Presence with First Commercial Shipment to Chile

  6/21/2022

  Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the expansion of its international presence with the commercial launch of its Lumivascular products in Chile.

• Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

  6/21/2022

  Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK.

• NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

  6/21/2022

  NeoGenomics, Inc. has announced new data in support of its RaDaRTM assay for the detection of minimal residual disease and recurrence in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

• Midatech Pharma PLC Announces MTX110 Development for the Treatment of Glioma

  6/21/2022

  Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following the submission of an application to the European Medicines Agency, its development programme of MTX110 for the treatment of glioma has been granted Orphan Medicinal Product designation by the agency.

• Lexaria Signs Manufacturing and License Agreements with BevNology

  6/21/2022

  Lexaria Bioscience Corp. is pleased to announce the signing of two agreements with Atlanta-based BevNology LLC ("BevNology").

• Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus

  6/21/2022

  Enzolytics, Inc. announced it has identified conserved, immutable sites on the Monkeypox virus.

• Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan

  6/21/2022

  Ainos, Inc. , today announced that the Company has begun marketing the Ainos SARS-CoV-2 Antigen Rapid Self-Test under an Emergency Use Authorization issued by the Taiwan Food and Drug Administration ("TFDA") on June 13, 2022 to Taiwan Carbon Nano Technology Corporation ("TCNT"), the manufacturer and product co-developer of the Test in conjunction with Ainos.

• 9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation

  6/21/2022

  9 Meters Biopharma, Inc. today announced completion of a pre-specified interim analysis for the Phase 3 study of larazotide, referred to as CedLara® (Celiac disease Larazotide), for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet.

• Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors

  6/20/2022

  Pharnext SA announces that at its Annual General Meeting on Friday June 17th all key resolutions proposed by the Pharnext Board of Directors were adopted.

• Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

  6/17/2022

  RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 3 to its Registration Statement on Form 20‑F with the U.S. Securities and Exchange Commission.

• Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

  6/17/2022

  Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine (mRNA-1273) in young children ages 6 months through 5 years of age at a dose level of 25 µg.

• NuGen Announces Results of its Annual and Special Meeting and Approval of Amendments to Stock Option Plan

  6/17/2022

  NuGen Medical Devices Inc. is pleased to announce that all matters submitted to shareholders for approval as set out in detail in the Company's management information circular dated May 17, 2022 were approved at the annual and special meeting of the shareholders of the Company held on June 17, 2022.

• Year-end Report 2021/2022 - Preparations for the Upcoming US Launch

  6/16/2022

  The high point of the quarter was when we submitted our 510(k) application to the US Food and Drug Administration (FDS) for market approval of DiviTum®TKa.

• Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease

  6/16/2022

  Biophytis SA announced that it is presenting new preclinical efficacy data for its product Sarconeos in SMA at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022.

• Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as New Board Members of BioInvent

  6/16/2022

  BioInvent International AB announces on behalf of the nomination committee, the proposal to elect Natalie Berner and Nanna Lüneborg as new Board members, at the Extraordinary General Meeting on July 12, 2022.

• Encision Reports Fourth Quarter Fiscal Year 2022 Results

  6/16/2022

  Encision Inc. announced financial results for its fiscal 2022 fourth quarter that ended March 31, 2022.

• Angle PLC Announces Predicting Immunotherapy Response in SCLC

  6/16/2022

  ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in small cell lung cancer patients using the Parsortix® system.

• NuGen M.D. Submits for FDA Emergency Use Authorization Approval for its Needle-Free Injection Systems

  6/15/2022

  NuGen Medical Devices Inc., a leader in needle-free drug delivery, in collaboration with Unifire Inc., a wholly owned subsidiary of Mission Ready Solutions submitted on June14th, 2022, an application to the U.S. Food and Drug Administration for Emergency Use Authorization of NuGen reusable needle-free jet injector systems.